RxSight, Inc. beat EPS estimates 75% of the time across 16 reported quarters (12 beats, 4 misses), averaging +12.2% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.37 | $-0.29 | +21.6% | Beat | Q2 FY26 call · transcript |
| Q1 FY26 | $-0.30 | $-0.38 | -26.7% | Miss | |
| Q4 FY25 | $-0.41 | $-0.22 | +46.3% | Beat | |
| Q3 FY25 | $-0.34 | $-0.24 | +29.4% | Beat | |
| Q2 FY25 | $-0.28 | $-0.29 | -3.6% | Miss | |
| Q1 FY25 | $-0.17 | $-0.20 | -17.6% | Miss | |
| Q4 FY24 | $-0.14 | $-0.15 | -7.1% | Miss | |
| Q3 FY24 | $-0.19 | $-0.16 | +15.8% | Beat | |
| Q2 FY24 | $-0.21 | $-0.16 | +23.8% | Beat | |
| Q1 FY24 | $-0.26 | $-0.25 | +3.9% | Beat | |
| Q4 FY23 | $-0.36 | $-0.26 | +27.8% | Beat | |
| Q3 FY23 | $-0.42 | $-0.35 | +16.7% | Beat |
Back to RXST overview · RXST holders · RXST KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.